MOLECULAR TARGETS and CANCER THERAPEUTICS | Zendy

Jianming Xu | Zendy; Lin Sheng | Zendy; Yan Wang | Zendy; Yuling Chen | Zendy; Ru Jia | Zendy; Jian Wang | Zendy; Ké Li | Zendy; Yang Sai | Zendy; Jing Li | Zendy; Chuan Qi | Zendy; Yi-Jun Hua | Zendy; Weiguo Su | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

MOLECULAR TARGETS and CANCER THERAPEUTICS

Author(s) -

Jianming Xu,

Lin Sheng,

Yan Wang,

Yuling Chen,

Ru Jia,

Jian Wang,

Ké Li,

Yang Sai,

Jing Li,

Chuan Qi,

Yi-Jun Hua,

Weiguo Su

Publication year - 2009

Publication title -

chemical and engineering news

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.114

H-Index - 43

eISSN - 1520-605X

pISSN - 0009-2347

DOI - 10.1021/cen-v087n036.p002

Subject(s) - citation , altmetrics , icon , social media , computer science , information retrieval , library science , world wide web , programming language

A1 First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors. Jian-Ming Xu, Lin Sheng, Yan Wang, Yu-Ling Chen, Ru Jia, Jian Wang, Ke Li, Yang Sai, Jing Li, Chuan Qi, Ye Hua, Wei-Guo Su. The 307th Hospital of Chinese People's Liberation Army, Beijing, China; Beijing Cancer Hospital, Beijing, China; Hutchison MediPharma Limited, Shanghai, China.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research